Published in Arzneimittelforschung on March 01, 1993
Hospital information management: the need for clinical leadership. BMJ (1995) 2.86
Examining the symptom experience of hospitalized patients using a pen-based computer. Proc AMIA Symp (1999) 0.78
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet (2000) 3.26
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Successful treatment of Bouveret's syndrome by endoscopic laserlithotripsy. Endoscopy (1999) 2.00
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol (2009) 1.81
Benefits and risks of needle-knife papillotomy. Gastrointest Endosc (1997) 1.80
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut (1998) 1.67
Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63
Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved. Arch Toxicol (1990) 1.59
Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf (2000) 1.51
Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer (2002) 1.46
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: a retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol (1997) 1.43
Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC). Onkologie (2004) 1.43
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol (2009) 1.39
Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer (2008) 1.39
Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques. Gastrointest Endosc (1999) 1.37
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer (2008) 1.29
Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer (1999) 1.27
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant (2000) 1.26
Abdominal actinomycosis: complication of endoscopic stenting in chronic pancreatitis? Endoscopy (2001) 1.23
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst (2000) 1.21
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer (2000) 1.19
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp (2011) 1.19
Differentiation and development of human female germ cells during prenatal gonadogenesis: an immunohistochemical study. Hum Reprod (2005) 1.16
Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology (1999) 1.16
Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer (2003) 1.12
Chemotherapy in elderly patients with colorectal cancer. Ann Oncol (2001) 1.12
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol (1998) 1.11
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol (2002) 1.11
Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol (1999) 1.10
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol (2002) 1.09
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol (2001) 1.09
Diagnosis and treatment of patients with testicular germ cell cancer. Drugs (1999) 1.08
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia (2008) 1.08
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs (2006) 1.08
Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost (2006) 1.08
Chemotherapy for renal cell carcinoma. Anticancer Res (1999) 1.07
Shockwave lithotripsy of salivary duct stones. Lancet (1992) 1.07
Wilms' tumor in the adolescent and adult. Eur Urol (1983) 1.06
p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene (1994) 1.06
Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer (1995) 1.05
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2010) 1.05
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol (2001) 1.04
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer (2001) 1.02
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol (2001) 1.02
Stem cell factor as a novel diagnostic marker for early malignant germ cells. J Pathol (2008) 1.00
Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report. J Med Case Rep (2008) 1.00
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer (1993) 0.99
25 years of endoscopic sphincterotomy in Erlangen: assessment of the experience in 3498 patients. Endoscopy (1998) 0.99
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol (2010) 0.98
Successful laserlithotripsy in Bouveret's syndrome using a new frequency doubled doublepulse Nd:YAG laser (FREDDY). Scand J Gastroenterol (2004) 0.98
Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol (2003) 0.98
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res (1999) 0.97
The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int (2002) 0.97
Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion (1999) 0.97
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer (2013) 0.96
Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood (1988) 0.96
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat (2009) 0.95
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs (2000) 0.95
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol (1991) 0.95
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs (2006) 0.94
Continuing medical education: a must for every medical oncologist. Ann Oncol (2003) 0.94
Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer (1999) 0.94
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer (2000) 0.94
Computerized ultrasound B-scan texture analysis of experimental diffuse parenchymal liver disease: correlation with histopathology and tissue composition. J Clin Ultrasound (1991) 0.94
Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol (1997) 0.93
Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs (1997) 0.93
The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology (1993) 0.93
Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer (1999) 0.93
Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology (1999) 0.93
Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer (1996) 0.93
Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer (1997) 0.92
A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol (1996) 0.92
Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer (1999) 0.92
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer (2014) 0.92
Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol (2000) 0.91
Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant (1996) 0.91
Contrast-enhanced ultrasound improves hepatic vessel visualization after orthotopic liver transplantation. Abdom Imaging (2002) 0.90
Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update. Int J Androl (2011) 0.90
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol (1998) 0.90
Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C. Dig Dis Sci (2000) 0.90
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs (2002) 0.90
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs (2008) 0.89